Clinical Characteristics of Myasthenia Gravis Patients with COVID-19 in Guangxi, China: A Case–Control Study

References

• Chen J, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Health West Pac. 2020;5:100063. doi:10.1016/j.lanwpc.2020.100063
   PubMedGoogle Scholar
• Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019;60(6):693–699. doi:10.1002/mus.26689
   PubMed Web of Science ®Google Scholar
• Nelke C, Stascheit F, Eckert C, et al. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflammation. 2022;19(1):89. doi:10.1186/s12974-022-02448-4
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Sahu P, Ranade AV, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020;96(1142):753–758. doi:10.1136/postgradmedj-2020-138234
   PubMed Web of Science ®Google Scholar
• Dewanjee S, Vallamkondu J, Kalra RS, et al. Emerging COVID-19 neurological manifestations: present outlook and potential neurological challenges in COVID-19 pandemic. Mol Neurobiol. 2021;58(9):4694–4715. doi:10.1007/s12035-021-02450-6
   PubMedGoogle Scholar
• Shah SMI, Yasmin F, Memon RS, et al. COVID-19 and myasthenia gravis: a review of neurological implications of the SARS-COV-2. Brain Behav. 2022;12(12):e2789. doi:10.1002/brb3.2789
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242. doi:10.1001/jama.2020.2648
   PubMed Web of Science ®Google Scholar
• Tugasworo D, Kurnianto A, Andhitara Y, et al. The relationship between myasthenia gravis and COVID-19: a systematic review. Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):83. doi:10.1186/s41983-022-00516-3
   PubMedGoogle Scholar
• Jakubikova M, Tyblova M, Tesar A, et al. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol. 2021;28(10):3418–3425. doi:10.1111/ene.14951
   PubMed Web of Science ®Google Scholar
• Kassardjian CD, Widdifield J, Paterson JM, et al. Serious infections in patients with myasthenia gravis: population-based cohort study. Eur J Neurol. 2020;27(4):702–708. doi:10.1111/ene.14153
   PubMed Web of Science ®Google Scholar
• Businaro P, Vaghi G, Marchioni E, et al. COVID-19 in patients with myasthenia gravis: epidemiology and disease course. Muscle Nerve. 2021;64(2):206–211. doi:10.1002/mus.27324
   PubMed Web of Science ®Google Scholar
• Camelo-Filho AE, Silva AMS, Estephan EP, et al. Myasthenia Gravis and COVID-19: clinical Characteristics and Outcomes. Front Neurol. 2020;11:1053. doi:10.3389/fneur.2020.01053
   PubMed Web of Science ®Google Scholar
• Fan Y, Li X, Zhang L, et al. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7(1):141. doi:10.1038/s41392-022-00997-x
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022;603(7902):700–705. doi:10.1038/s41586-022-04462-1
   PubMed Web of Science ®Google Scholar
• De Leon AM, Aban I, McPherson T, et al. Impact of the COVID-19 pandemic on patients with myasthenia gravis: a survey of the myasthenia gravis foundation of America MG patient registry. Muscle Nerve. 2023;67(1):25–32. doi:10.1002/mus.27743
   PubMed Web of Science ®Google Scholar
• Zanza C, Romenskaya T, Manetti AC, et al. Cytokine Storm in COVID-19: immunopathogenesis and Therapy. Medicina. 2022;58(2). doi:10.3390/medicina58020144
   Google Scholar
• Tutal Gursoy G, Yuksel H, Mulkem Simsek I, et al. Neurological presentations in patients with COVID-19 in cytokine storm. Can J Neurol Sci. 2023;50(1):89–95. doi:10.1017/cjn.2021.247
   PubMed Web of Science ®Google Scholar
• Nasrollahi H, Talepoor AG, Saleh Z, et al. Immune responses in mildly versus critically ill COVID-19 patients. Front Immunol. 2023;14:1077236. doi:10.3389/fimmu.2023.1077236
   PubMedGoogle Scholar
• Dotan A, David P, Arnheim D, Shoenfeld Y. The autonomic aspects of the post-COVID19 syndrome. Autoimmun Rev. 2022;21(5):103071. doi:10.1016/j.autrev.2022.103071
   PubMed Web of Science ®Google Scholar
• Octaviana F, Yugo HP, Safri AY, et al. Case series: COVID-19 in patients with mild to moderate myasthenia gravis in a National Referral Hospital in Indonesia. eNeurologicalSci. 2021;23:100332. doi:10.1016/j.ensci.2021.100332
   PubMedGoogle Scholar
• Stascheit F, Grittner U, Hoffmann S, et al. Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis. J Neurol. 2023;270(1):1–12. doi:10.1007/s00415-022-11389-0
   PubMed Web of Science ®Google Scholar
• Zupanic S, Lazibat I, Rubinic Majdak M, Jelicic M. Treatment of myasthenia gravis patients with Covid-19: review of the literature. Acta Clin Croat. 2022;60(3):496–509. doi:10.20471/acc.2021.60.03.21
   PubMed Web of Science ®Google Scholar
• Jacob S, Muppidi S, Guidon A, et al.; International MGC-WG. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;412:116803. doi:10.1016/j.jns.2020.116803
   PubMed Web of Science ®Google Scholar
• Sole G, Mathis S, Friedman D, et al. Impact of coronavirus disease 2019 in a French cohort of myasthenia gravis. Neurology. 2021;96(16):e2109–e2120. doi:10.1212/WNL.0000000000011669
   PubMed Web of Science ®Google Scholar
• Ward D, Gortz S, Thomson Ernst M, et al. The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. Eur Respir J. 2022;59(4):2100769. doi:10.1183/13993003.00769-2021
   PubMed Web of Science ®Google Scholar
• Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833–1839. doi:10.1016/j.jiph.2020.07.014
   PubMed Web of Science ®Google Scholar
• Karimi N, Fatehi F, Okhovat AA, et al. Clinical features and outcomes of patients with myasthenia gravis affected by COVID-19: a single-center study. Clin Neurol Neurosurg. 2022;222:107441. doi:10.1016/j.clineuro.2022.107441
   PubMed Web of Science ®Google Scholar
• Bakirtzis C, Boziki MK, Karakasi MV, Moysiadis T, Grigoriadis N. The impact of SARS-CoV −2 immunization on COVID −19 disease course in people with myasthenia gravis. Muscle Nerve. 2023;67:412–416. doi:10.1002/mus.27805
   PubMed Web of Science ®Google Scholar
• Ruan Z, Tang Y, Li C, et al. COVID-19 vaccination in patients with myasthenia gravis: a single-center case series. Vaccines. 2021;9(10). doi:10.3390/vaccines9101112
   Web of Science ®Google Scholar
• Lupica A, Di Stefano V, Iacono S, et al. Impact of COVID-19 in AChR myasthenia gravis and the safety of vaccines: data from an Italian cohort. Neurol Int. 2022;14(2):406–416. doi:10.3390/neurolint14020033
   PubMed Web of Science ®Google Scholar
• Farina A, Falso S, Cornacchini S, et al. Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: a multicenter experience. Eur J Neurol. 2022;29(8):2505–2510. doi:10.1111/ene.15348
   PubMed Web of Science ®Google Scholar
• Aktoz G, Boz C, Zengin S, et al. Clinical course and outcome of Covid-19 in patients with myasthenia gravis. Neurol Res. 2023:1–7. doi:10.1080/01616412.2023.2167536
   Web of Science ®Google Scholar
• Kopanska M, Batoryna M, Bartman P, Szczygielski J, Banas-Zabczyk A. Disorders of the cholinergic system in COVID-19 Era-A review of the latest research. Int J Mol Sci. 2022;23(2). doi:10.3390/ijms23020672
   Web of Science ®Google Scholar
• Sriwastava S, Tandon M, Kataria S, Daimee M, Sultan S. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review. J Neurol. 2021;268(8):2690–2696. doi:10.1007/s00415-020-10263-1
   PubMed Web of Science ®Google Scholar
• Abicic A, Sitas B, Adamec I, Bilic E, Habek M. New-onset ocular myasthenia gravis after booster dose of COVID-19 vaccine. Cureus. 2022;14(7):e27213. doi:10.7759/cureus.27213
   PubMed Web of Science ®Google Scholar